As the race to develop a COVID-19 vaccine intensifies, nations are already ramping up production capacity on a scale never seen before – but what does this mean for manufacturers? Here, Rod Schregardus makes the case for advanced planning and scheduling techniques in new and existing facilities.
ACROSS EUROPE, plans to mass produce a COVID-19 vaccine are quickly ramping up. For example, Sanofi is investing more than half a billion euros in a state-of-the-art production site in Neuville sur Saône as well as a new vaccine research centre in Marcy-l’Etoile.1 Meanwhile, Novavax is using its recently acquired manufacturing facility in Bohumil in the Czech Republic to produce its own vaccine candidate.2
As well as funding research, the UK government has also pledged £100 million to produce a vaccine at scale at the Cell and Gene Therapy Catapult Manufacturing Innovation Centre in Braintree, Essex and £93 million for the Vaccines Manufacturing and Innovation Centre (VMIC) in Oxfordshire. A further £38 million will ensure a rapid deployment facility can begin manufacturing,3 while a deal with Wockhardt will see a fill and finish line start this year at the firm’s subsidiary, CP Pharmaceuticals in North Wales.4
Ramping up production
The rate at which COVID-19 vaccine programmes are moving is unprecedented. Never before have we seen companies rushing to develop and manufacture a product on this scale. Of course, this haste is hardly surprising, given the impact the virus has had on public health, healthcare systems, economies and education. Many believe we can only emerge from the crisis when there is a safe and effective vaccine that is available to a country’s entire population at a relatively affordable price. However, companies must remain mindful of the viability and safety of these vaccines before rolling them out in order to avoid a potentially catastrophic situation.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
It has been a year of rapidly formed partnerships and new deals as countries try to secure millions of doses of particular vaccines ahead of approval. The UK alone has ordered 340 million doses from six companies – far more than a country with 66 million people would need – because there may be variations in how different segments of the population respond.5
Until recently, it would also have been difficult to imagine a company building parallel supply chains like AstraZeneca has in order to create sufficient capacity to deliver two billion doses of the Oxford (AZD1222) vaccine worldwide. This is partly due to the development of strategic partnerships, such as the deal it struck with Serum Institute in India, enabling the company to be on track to provide ‘broad and equitable access’ to the vaccine.6
Risk management
Capacity is not the only consideration, of course – understanding risk is also crucial. Remember that the industry’s complex global supply chains were called into question at the height of the pandemic when factory shutdowns in India and China could have threatened the global supply of life-saving drugs. It is still too early to say how much established supply chains will change as a result of the crisis; however, as the authors of one report state: “The intense focus on risk management across networks and supply chains will likely continue, despite the inevitable increased costs.”7
Forward planning
Increasing capacity at scale, while managing the enormous risk this brings, demands investment in a company’s capabilities and collaboration with carefully chosen contract manufacturing organisations (CMOs). The timeframes manufacturers are working to have never been more compressed and they have no choice but to start scaling up before a vaccine is approved. In these extraordinary times, the financial shortfall dwarfs in comparison with the damage the virus could cause in the event of another large‑scale outbreak.
Government funding and advance orders might mitigate at least some of the financial risks, however, companies are still taking a big gamble, not least because the precise manufacturing processes still need to be refined. Currently, we do not know how long it will take to produce a single batch, let alone supply an entire country. The learning curve may be steep – but there are steps that can be taken to limit the risks ahead of these facilities becoming operational.
Capacity is not the only consideration, of course – understanding risk is also crucial”
Advanced planning and scheduling (APS) methods are critical when working at this scale as they can help planners and other stakeholders understand a facility’s capabilities before production starts. Even if they only have data from a limited number of initial batch runs they can use rapid modelling and ‘what if?’ scenario planning to determine whether there is enough capacity to produce the required doses of a vaccine within the timescale. Identifying roadblocks early in the process offers a chance to resolve them quickly, reducing the risk of error and missed deadlines.
When it comes to day-to-day planning and scheduling, maintaining consistency is key no matter what the drug or vaccine is. Without this, manufacturers run the risk of encountering problems with batch yield or face increasing struggles to maximise outturn. Spreadsheets can be used to schedule complex and time-sensitive processes, but recent events which saw nearly 16,000 COVID-19 tests misplaced as a result of Public Health England using outdated Microsoft Excel files, demonstrate that this way of working is simply not reliable when there is so much at stake. However, sophisticated software applications will ensure consistency is maintained while maximising outturn – especially when delivery times are tight.
We must remember that this is a novel vaccine and even the most experienced planner cannot predict every variable. Teams may be working together at new facilities for the first time, so they will need actionable insights, based on real-time production data, to make effective decisions at speed. Furthermore, lack of visibility means it is easy to miss some of the obvious barriers to efficiency and productivity. Oversights with machine maintenance in the master schedule, for example, could lead to unnecessary downtime, while lining up every task for a Monday morning could result in bottlenecks. Advanced planning and scheduling can automate manual tasks, considering every variable and constraint to determine whether a product can be delivered at the right volume to the timescale agreed. It also aids understanding of the impact on the production of other drugs, so companies can make sure supplies are not disrupted overall. Importantly, it reduces the chance of human error when scheduling inter-dependent processes and makes the most of capacity at a time when no company can afford for its resources to be under-utilised.
Automating processes
This does not mean the skills and experience of production planners are no longer needed – quite the opposite, in fact. Automating manual processes frees these workers up to concentrate on tasks that add essential value at this critical time.
The risks involved in developing and delivering a vaccine at this scale are clear and manufacturers must ensure they are able to fulfil the orders they receive. Any mistakes or hold-ups and the revenue generated from advance orders will quickly disappear. Pharmaceutical companies are currently under intense scrutiny and cannot afford the commercial impact and damage a delay would cause to their long-term credibility.
The development of a COVID-19 vaccine has been characterised by innovation and collaboration between governments, universities and pharmaceuticals companies at every step. The lessons we learn from this crisis could well pave the way for a closer alliance between R&D and manufacturing, with new generations of therapies being produced in Europe. We may see supply chains recalibrated to ensure nations are not impacted by future stocks, as well as the creation of more quality jobs in the life sciences industry.
Whether they are investing in a new facility, scaling up at an existing one or want to be more competitive in a global market, companies will rely on digital technologies to embed good manufacturing practices (GMP) from the start. Advanced planning, artificial intelligence (AI) and the Internet of Things (IoT) all present exciting opportunities to reduce the time it takes to deliver products to market and control costs. In a year when certainty has been in short supply, data‑driven production planning and modelling gives manufacturers the capabilities and confidence to rise to whatever challenge they face next.
About the author
Rod Schregardus is an expert in day-today scheduling, capacity planning and what-if analysis at The Access Group. He works with industry-leading pharma and biopharma companies in the US and UK to help improve efficiency and productivity.
References
Sanofi invests to make France its world class center of excellence in vaccine research and production. Available from www.sanofi.com/en/media-room/press-releases [Accessed 8 Sept. 2020]
Kelleher, Katie; Kumar, Ketan; Patel Parag and Ulf Schrader. Pharma operations: The path to recovery and the next normal. Available from Pharma operations: The path to recovery and the next normal. [Accessed 8 Sept. 2020]
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.